IRadimed Corp. Hits New 52-Week High of $87.88, Up 104%

IRadimed Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 87.88 on November 4, 2025. This achievement underscores the company's robust performance over the past year, with a remarkable 104.08% increase compared to the S&P 500's 19.89% gain.
The company's market capitalization stands at USD 914 million, reflecting its position within the small-cap category. IRadimed boasts a price-to-earnings (P/E) ratio of 39.00, indicating a premium valuation relative to its peers. Additionally, the stock's price-to-book ratio is 9.69, further emphasizing its attractive valuation metrics.

IRadimed has demonstrated strong financial health, highlighted by a return on equity (ROE) of 21.91% and a low debt-to-equity ratio of -0.56. The company has consistently reported positive results over the last four quarters, with operating cash flow reaching a high of USD 19.4 million and net sales peaking at USD 20.41 million. With a solid annual growth rate of 56.09% in operating profit, IRadimed Corp. continues to solidify its position in the market.